French | English

Home : Investors > AMF regulated information > Press releases

Contact us

Questions about the Group, products, the financial statements?

> Please fill in this form

Where to meet us?

> View the Group's agenda

Press releases

13/05/2013

BioAlliance Pharma announces DSMB second positive recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer (PDF - 240 Ko)

Publication du Document de Référence 2012 (PDF - 59 Ko)

15/04/2013

BioAlliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013 (PDF - 166 Ko)

15/04/2013

BioAlliance Pharma's Sitavig® receives Market Authorization in the US for the treatment of Herpes Labialis (PDF - 73 Ko)

12/03/2013

BioAlliance Pharma pursues the development plan of its Loramyc® in Japan through its partner Sosei - Initiation of the pivotal registration phase III trial (PDF - 162 Ko)

28/02/2013

BioAlliance Pharma signs a collaborative agreement with one of the worldwide leaders in vaccines for a vaccine application of its patented Lauriad® mucoadhesive technology (PDF - 163 Ko)

Emission d'actions PACEO 260213 (PDF - 89 Ko)

14/02/2013

BioAlliance Pharma announces the forthcoming extension of its phase II clinical trial with Validive® in the United States (PDF - 323 Ko)

Next » 1 | 2